FR20C1016I2 - Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales - Google Patents

Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales

Info

Publication number
FR20C1016I2
FR20C1016I2 FR20C1016C FR20C1016C FR20C1016I2 FR 20C1016 I2 FR20C1016 I2 FR 20C1016I2 FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 C FR20C1016 C FR 20C1016C FR 20C1016 I2 FR20C1016 I2 FR 20C1016I2
Authority
FR
France
Prior art keywords
vesicular stomatitis
stomatitis virus
against viral
viral hemorrhagic
recombinant vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1016C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Canada
Original Assignee
Health Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Canada filed Critical Health Canada
Publication of FR20C1016I1 publication Critical patent/FR20C1016I1/fr
Application granted granted Critical
Publication of FR20C1016I2 publication Critical patent/FR20C1016I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR20C1016C 2002-07-26 2020-05-06 Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales Active FR20C1016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39855202P 2002-07-26 2002-07-26
PCT/CA2003/001125 WO2004011488A2 (en) 2002-07-26 2003-07-28 Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

Publications (2)

Publication Number Publication Date
FR20C1016I1 FR20C1016I1 (enExample) 2020-06-12
FR20C1016I2 true FR20C1016I2 (fr) 2022-04-01

Family

ID=31188416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1016C Active FR20C1016I2 (fr) 2002-07-26 2020-05-06 Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales

Country Status (9)

Country Link
US (1) US8012489B2 (enExample)
EP (1) EP1527087B2 (enExample)
AT (1) ATE455124T1 (enExample)
AU (1) AU2003250680A1 (enExample)
CA (1) CA2493142C (enExample)
DE (1) DE60330966D1 (enExample)
ES (1) ES2338416T5 (enExample)
FR (1) FR20C1016I2 (enExample)
WO (1) WO2004011488A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116983A2 (en) * 2007-12-18 2009-09-24 Trustees Of Boston University Compositions and methods for treating ebola virus infection
US8796013B2 (en) 2007-12-18 2014-08-05 Trustees Of Boston University Pre-or post-exposure treatment for filovirus or arenavirus infection
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
KR101723900B1 (ko) 2009-06-08 2017-04-07 더 유니버시티 오브 웨스트 온타리오 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
US9402891B2 (en) * 2011-06-08 2016-08-02 Ohio State Innovation Foundation Norovirus immunogens and related materials and methods
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
US20200181678A1 (en) * 2016-12-15 2020-06-11 Merck Sharp & Dohme Corp. Cell-Based Reporter Assay for Live Virus Vaccines
EP3681523A4 (en) * 2017-09-15 2021-12-29 The Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
TW202600150A (zh) 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
US11274282B2 (en) 2019-05-15 2022-03-15 Board Of Regents, The University Of Texas System Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
IL297237B2 (en) 2020-04-17 2025-08-01 Regeneron Pharma Detection assays for coronavirus neutralizing antibodies
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
CN117925662B (zh) * 2023-12-19 2024-08-13 军事科学院军事医学研究院军事兽医研究所 一种重组水泡性口炎病毒以及埃博拉出血热感染动物模型的构建方法
WO2025208054A1 (en) 2024-03-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Recombinant rhabdovirus encoding interleukin-12 (il-12)
CN120966775B (zh) * 2025-10-21 2026-02-03 浙江迪福润丝生物科技股份有限公司 一种携带马尔堡病毒缺陷型g蛋白的无神经毒性vsv载体重组溶瘤病毒

Also Published As

Publication number Publication date
ATE455124T1 (de) 2010-01-15
EP1527087A2 (en) 2005-05-04
WO2004011488A3 (en) 2004-04-15
FR20C1016I1 (enExample) 2020-06-12
ES2338416T3 (es) 2010-05-07
CA2493142C (en) 2013-11-12
AU2003250680A1 (en) 2004-02-16
WO2004011488A2 (en) 2004-02-05
EP1527087B2 (en) 2013-07-17
CA2493142A1 (en) 2004-02-05
US8012489B2 (en) 2011-09-06
US20060193872A1 (en) 2006-08-31
DE60330966D1 (de) 2010-03-04
AU2003250680A8 (en) 2004-02-16
EP1527087B1 (en) 2010-01-13
ES2338416T5 (es) 2013-11-20
WO2004011488A9 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
FR20C1016I1 (enExample)
IL238584A0 (en) Highly calibrated recombinant influenza viruses for use in vaccines and gene therapy
IL163646A0 (en) Recombinant parainfluenza virus expression systemsand vaccines comprising heterologous antigens derived from metapneumovirus
UA85536C2 (en) Viral antigens
EP1622574A4 (en) EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
ATE368729T1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
ZA201009135B (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
AU2003279240A8 (en) Methods for purifying viral particles for gene therapy
EP1485488A4 (en) RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
AU2002318104A1 (en) Microparticles and methods for delivery of recombinant viral vaccines
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.
AU2003240866A1 (en) Antibodies, peptides and vaccines against hiv-1 virus
HK1073475A (en) Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
HK1067371A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
HK1067035A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
GB0213446D0 (en) Methods for making recombinant viruses and vaccines